Beam Therapeutics Inc

NASDAQ:BEAM  
67.90
+1.77 (+2.68%)
Products, Strategic Combinations

Pfizer And Beam Enter Exclusive Multi-Target Research Collaboration

Published: 01/10/2022 11:57 GMT
Beam Therapeutics Inc (BEAM) - :pfizer and Beam Enter Exclusive Multi-target Research Collaboration to Advance Novel in Vivo Base Editing Programs for a Range of Rare Disease.
Pfizer - Beam to Receive Upfront Payment of $300 Million Under Collaboration.
Pfizer - Under Collaboration, Beam to Be Eligible to Receive Milestone Payments of Up $1.05 Billion for Potential Total Consideration of Up to $1.35 Billion.
Pfizer - Beam May Opt Into a Global Co-development & Co-commercialization Agreement for One Program Under Collaboration.
Pfizer - Beam to Conduct All Research Activities Through Development Candidate Selection for 3 Undisclosed Targets Not Included in Beam’s Existing Programs.
Pfizer - May Opt in to Exclusive, Worldwide Licenses to Each Development Candidate, After Which It Will Be Responsible for All Development Activities.
Pfizer - Beam is Also Eligible to Receive Royalties on Global Net Sales for Each Licensed Program.
Pfizer - Collaboration Has Initial Term of 4 Yrs & May Be Extended Up to 1 Additional Year.
Pfizer - If Beam Opts in to Global Co-development & Co-commercialization Agreement, Pfizer & Beam Would Share Net Profits, Costs in 65%/35% Ratio.